Signals, Powered By EquityPandit
Alembic Pharmaceuticals has received tentative approval from USFDA, for Ticagrelor tablets,90 mg.
The tentatively approved abbreviated new drug application (ANDA) Ticagrelor Tablets, 90 mg is therapeutically equivalent to the reference listed drug product (RLD), Brilinta Tablets, 90 mg, of Astrazeneca Pharmaceuticals LP.
Further, the approved tablets are suggested to reduce the rate of cardiovascular death, myocardial infarction, and stroke in patients with acute coronary syndrome (ACS) or a history of myocardial infarction (Ml).
